Christopher Peetz Sells 20,000 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz sold 20,000 shares of the business’s stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $122.27, for a total value of $2,445,400.00. Following the sale, the chief executive officer owned 194,309 shares of the company’s stock, valued at $23,758,161.43. The trade was a 9.33% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christopher Peetz also recently made the following trade(s):

• On Monday, June 1st, Christopher Peetz sold 30,000 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $95.84, for a total transaction of $2,875,200.00.

Mirum Pharmaceuticals Stock Down 0.7%

Shares of NASDAQ MIRM opened at $127.70 on Friday. The company has a current ratio of 2.09, a quick ratio of 1.99 and a debt-to-equity ratio of 1.28. Mirum Pharmaceuticals, Inc. has a 12-month low of $50.25 and a 12-month high of $130.00. The company has a market cap of $7.79 billion, a P/E ratio of -9.38 and a beta of 0.48. The stock has a fifty day moving average price of $105.93 and a 200 day moving average price of $97.55.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its earnings results on Wednesday, May 6th. The company reported ($13.43) EPS for the quarter, missing the consensus estimate of ($0.75) by ($12.68). Mirum Pharmaceuticals had a negative net margin of 140.24% and a negative return on equity of 11.28%. The company had revenue of $159.88 million for the quarter, compared to analysts’ expectations of $148.21 million. During the same quarter in the previous year, the business posted ($0.30) earnings per share. The business’s quarterly revenue was up 43.3% compared to the same quarter last year. Research analysts anticipate that Mirum Pharmaceuticals, Inc. will post -2.01 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on MIRM. Royal Bank Of Canada raised their price target on shares of Mirum Pharmaceuticals from $142.00 to $148.00 and gave the stock an “outperform” rating in a research report on Tuesday. Evercore reaffirmed an “outperform” rating and set a $138.00 target price on shares of Mirum Pharmaceuticals in a report on Thursday, May 7th. CLSA set a $146.00 price objective on shares of Mirum Pharmaceuticals in a report on Monday, June 15th. Stifel Nicolaus set a $136.00 target price on Mirum Pharmaceuticals in a research report on Thursday, May 7th. Finally, Citizens Jmp raised their target price on shares of Mirum Pharmaceuticals from $140.00 to $146.00 and gave the company a “market outperform” rating in a research note on Monday, June 15th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Mirum Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $143.40.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Large investors have recently made changes to their positions in the company. Contravisory Investment Management Inc. raised its stake in Mirum Pharmaceuticals by 2.3% during the 2nd quarter. Contravisory Investment Management Inc. now owns 4,604 shares of the company’s stock valued at $539,000 after purchasing an additional 103 shares during the period. Faithward Advisors LLC raised its holdings in Mirum Pharmaceuticals by 0.5% during the first quarter. Faithward Advisors LLC now owns 27,467 shares of the company’s stock valued at $2,537,000 after buying an additional 126 shares in the last quarter. Janney Montgomery Scott LLC lifted its holdings in Mirum Pharmaceuticals by 6.7% in the 4th quarter. Janney Montgomery Scott LLC now owns 3,200 shares of the company’s stock worth $253,000 after purchasing an additional 200 shares during the last quarter. Comerica Bank boosted its holdings in shares of Mirum Pharmaceuticals by 45.1% during the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after buying an additional 278 shares during the period. Finally, Osaic Holdings Inc. boosted its holdings in Mirum Pharmaceuticals by 46.5% during the second quarter. Osaic Holdings Inc. now owns 1,106 shares of the company’s stock valued at $56,000 after acquiring an additional 351 shares during the period.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.